A single site study to investigate the current prevalence of anti-hepatitis C virus antibody among substance use disorder patients in Hiroshima-Insufficient testing and diagnosis.

Kagaya, Ariyuki; Nagaoki, Yuko; Shimura, Satomi; Kawana, Katsuyoshi; Chayama, Kazuaki

Kagaya, Ariyuki; Nagaoki, Yuko; Shimura, Satomi; Kawana, Katsuyoshi; Chayama, Kazuaki.

Affiliation

Kagaya A; KONUMA Memorial Institute of Addiction and Mental Health, Hiroshima, Japan.
Nagaoki Y; Department of Gastroenterology, Mazda Hospital, Mazda Motor Corporation, Hiroshima, Japan.
Shimura S; AbbVie GK, Tokyo, Japan.
Kawana K; AbbVie GK, Tokyo, Japan.
Chayama K; Department of Collaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Neuropsychopharmacol Rep ; 43(4): 521-531, 2023 Dec.

Article de En | MEDLINE | ID: mdl-37193604

Sujet(s)
Mots clés

HCV seroprevalence; harm reduction; hepatitis C virus; people who inject drugs; people who use drugs

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Toxicomanie intraveineuse / Hépatite C / Troubles liés à une substance Type d'étude: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Neuropsychopharmacol Rep Année: 2023 Type de document: Article Pays d'affiliation: Japon Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google